Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Elevance Health, Inc.

In trading on Friday, shares of Elevance Health Inc (Symbol: ELV) crossed above their 200 day moving average of $353.89, changing hands as high as $356.94 per share. Elevance Health Inc shares are currently trading up about 1.1% on the day. The chart below shows the one year performance of ELV shares, versus its 200 day moving average:
Looking at the chart above, ELV's low point in its 52 week range is $273.71 per share, with $458.75 as the 52 week high point — that compares with a last trade of $353.91. The ELV DMA information above was sourced from TechnicalAnalysisChannel.com
Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average »
Also see:
Top Stocks Held By Andreas Halvorsen
Funds Holding VACC
FEZ market cap history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ELV Makes Bullish Cross Above Critical Moving Average

U.S. managed healthcare insurers are currently going through a significant transformation, driven by rising medical costs, increased regulatory scrutiny and a surge in investments focused on data, analytics and value-based care. At the same time, scale, diversification across insurance and services, and disciplined capital allocation are becoming increasingly important as payers look to protect margins while sustaining long-term growth. Against this backdrop, UnitedHealth Group UNH and Elevance Health, Inc. ELV stand out as two of the largest players in the health insurance and managed care space.
Both companies have a strong presence in the commercial, Medicare and Medicaid sectors, making them key players in the U.S. healthcare landscape. Although UNH and ELV target similar markets, they take different paths in terms of strategy, business composition and how they integrate care delivery, services and technology. These differences shape their revenue streams, cost management strategies and the risks they face from regulations and reimbursements.
Let’s dive deep and closely compare the fundamentals to determine which stock offers greater upside right now.
The Case for UnitedHealth
UNH, with a market cap of nearly $298 billion, stands as the largest health insurer in the United States, but its business model goes far beyond just traditional insurance. Alongside its core UnitedHealthcare segment, it operates Optum, a comprehensive healthcare services unit that covers everything from pharmacy benefits to care delivery and health analytics. This setup enables UNH to engage at various stages of the healthcare value chain, providing a level of diversification and operational leverage that few competitors can rival.
Scale is a key part of UNH’s strategy. With its large member base and extensive reach across the country, the company gathers valuable data insights and has a strong operational presence throughout the healthcare landscape. This wide-ranging approach allows for ongoing investments in technology, analytics and artificial intelligence, which will help the company streamline claims processes, improve care coordination and gain better visibility into medical cost trends across its various operations. Its UnitedHealthcare business catered to 50.1 million people as of Sept. 30, 2025, which grew 1.6% year over year.
The company’s total revenues rose 11.6% year over year in the first nine months of 2025, with 15% growth at UnitedHealthcare and 6.6% growth at Optum, driven by growth in domestic commercial membership and strength witnessed in Optum Rx. The Optum brand continues to be a long-term growth driver. However, the Department of Justice (DOJ) is reportedly investigating the company for Medicare billing practices, reimbursement policies and OptumRx pharmacy benefits operations.
UnitedHealth has been actively reshaping its portfolio through a series of divestitures and proposed asset sales as part of a broader effort to sharpen its strategic focus and address regulatory challenges. To streamline operations, it is pressing ahead with its exit from Latin America. Per Reuters, the company recently agreed to sell its final South American operation, Banmedica, to Patria Investments for $1 billion. This move follows earlier divestitures in Brazil and Peru, marking another step in narrowing the company’s strategic focus. Also in the United States, the push to finalize its merger with Amedisys has led to the need to sell off some healthcare facilities to address antitrust issues. As part of a settlement with the DOJ, the companies plan to offload at least 164 home health and hospice locations across 19 states.
Financially, UnitedHealth is in a solid position. The company ended the third quarter of 2025 with $30.6 billion in cash and short-term investments — sufficient to cover its short-term borrowings and current maturities of long-term debt, which stands at $7.7 billion. Its total debt-to-capital of 41.6% is below ELV’s 42% and the industry’s 44.3%. UNH missed earnings estimates twice in the past four quarters and beat on the other occasions.
UnitedHealth Group Incorporated Price, Consensus and EPS Surprise
UnitedHealth Group Incorporated price-consensus-eps-surprise-chart | UnitedHealth Group Incorporated Quote
However, rising medical utilization has squeezed profit margins, especially in the MA business. In the third quarter of 2025, the company’s medical care ratio rose to 88.1% compared with 84.9% the previous year, indicating that rising medical costs are eating into the premiums collected. Medical costs surged 17.7% year over year in the first three quarters; we expect them to rise 18.5% in 2025.
The Case for Elevance Health
ELV, with a market cap of $77.4 billion, has positioned itself as a diversified managed care organization, focusing on growth and running its operations smoothly. In addition to core health coverage, the company provides a wide array of healthcare solutions, including pharmacy, dental, vision and behavioral health services, all while continuously enhancing its integrated care offerings.
A central pillar of Elevance Health’s strategy is its Carelon division, which integrates care delivery, data analytics and digital health services. The company aims to enhance efficiency and outcomes by coordinating care across hospitals, clinics, home-based services, behavioral health providers and virtual care channels. Carelon’s operating revenues rose 35.4% year over year, driven largely by buyouts and risk-based solutions scaling. Carelon platform is driving digital and AI-enabled solutions to personalize care, cut costs and sharpen margins.
ELV’s total revenues rose 13.9% year over year in the first nine months of 2025, aided by strong growth in premiums, product revenues and net investment income. The favorable top-line trend is likely to continue in the long run, given its strong business, membership growth and significant new contracts in its government business. It beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 6.4%.
Elevance Health, Inc. Price, Consensus and EPS Surprise
Strategic acquisitions and partnerships position the company for long-term growth. Acquisitions, such as Beacon Health, Paragon Healthcare, Inc. and Kroger’s Specialty Pharmacy, have strengthened ELV’s portfolio. The divestment of its Life and Disability business to StanCorp allowed the reallocation of resources to more profitable areas. Also, ELV is reshaping its Medicare strategy by stepping away from certain underperforming Medicare Advantage markets and fully exiting the standalone Part D segment.
However, Elevance Health is contending with elevated costs, primarily from higher medical benefit expenses and product costs. Total expenses rose 15% year over year in the first nine months of 2025. The company’s benefit expense ratio deteriorated to 88.9% in the first nine months of 2025 from 87.2% a year earlier, and is expected to reach 90% in 2025, reflecting pressure from unfavorable cost trends in ACA and Medicaid businesses amid insufficient rate adjustments.
How Do the Estimates Compare for UNH & ELV?
Both companies are contending with unfavorable estimates from analysts for 2025 earnings due to the rising cost trend. The Zacks Consensus Estimate for UNH’s 2025 revenues indicates 11.9% year-over-year growth, but the same for EPS signals a massive 41.1% decline. On the other hand, the consensus estimate for ELV’s 2025 earnings indicates a 9.2% decline from a year ago, while the same for revenues suggests 12.9% growth.
Valuation: UNH vs. ELV
Valuation favors ELV. In comparison, UNH trades at a forward P/E of 18.69X, above the industry average of 15.54X and ELV’s 12.68X. This valuation gap gives ELV a more attractive risk-reward profile. In contrast, UNH’s premium pricing could limit near-term upside unless it delivers clear margin improvements. Both companies currently carry a Value Score of A.
Image Source: Zacks Investment Research
Price Performance Comparison
In the past three months, UNH faced sell-offs tied to medical costs and investigation concerns. Its shares declined 4.8% during the same time. Meanwhile, ELV shares have jumped 7.8%, outperforming the S&P 500 Index.
3-Month Price Performance – UNH, ELV & S&P 500
Image Source: Zacks Investment Research
Conclusion
UnitedHealth and Elevance Health are currently navigating a tough managed care environment, facing challenges like rising medical costs and regulatory pressures. While UnitedHealth boasts an impressive scale and the Optum platform, which offers significant long-term strategic benefits, it is still grappling with short-term margin pressures and ongoing regulatory concerns that are impacting its outlook.
On the other hand, Elevance Health seems to be in a better position right now, supported by strategic exits from underperforming markets, the growing Carelon platform and a more appealing valuation. Even though both companies currently carry a Zacks Rank #3 (Hold), ELV offers a relatively stronger near-term risk-reward profile.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
#1 Semiconductor Stock to Buy (Not NVDA)
The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.
One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

UNH vs. ELV: Which Managed Care Stock Has the Edge Today?

Below is Validea's guru fundamental report for ELEVANCE HEALTH INC (ELV). Of the 22 guru strategies we follow, ELV rates highest using our Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.
ELEVANCE HEALTH INC (ELV) is a large-cap value stock in the Insurance (Accident & Health) industry. The rating using this strategy is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of ELEVANCE HEALTH INC
More Information on Martin Zweig
About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in "Dirty Harry", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.
Additional Research Links
Dividend Aristocrats 2025
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ELV Quantitative Stock Analysis - Martin Zweig

For UnitedHealth Group UNH, artificial intelligence (AI) has evolved from a concept to a crucial part of its strategy. The healthcare industry’s heavy administrative tasks, like handling claims manually, data fragmentation and complex billing processes, have squeezed profit margins for a long time. AI offers a pathway to streamline these processes, to boost efficiency and reduce costs, while maintaining the quality of care.
UNH is harnessing the power of AI to streamline various processes like claims handling, prior authorizations, fraud detection and customer support. These tasks often involve a lot of repetitive, rule-based work that leads to delays and errors. By automating decision-making and data checks, AI can help speed up processing times, boost accuracy and reduce friction among providers, payers and patients.
From a strategic standpoint, UNH’s scale gives it an advantage. Having access to extensive datasets from insurance, pharmacy and care delivery opens opportunities to develop more effective models and standardize processes at scale. However, AI adoption is not without challenges. Regulatory scrutiny around data privacy, algorithmic bias and transparency is intensifying, particularly in healthcare. UNH must balance innovation with compliance, ensuring AI tools support informed decision-making while maintaining the trust of regulators, providers and members.
AI is not going to eliminate administrative waste at UNH overnight. Its effectiveness will depend on how thoughtfully it is integrated into existing workflows and governed over time. If deployed with clear oversight, strong data discipline, and measurable efficiency goals, AI could gradually ease operational hurdles and boost the company’s capacity to handle the growing complexities of the healthcare landscape.
How Are Competitors Faring?
Some of UNH’s major competitors in the AI-enabled healthcare solutions are Elevance Health, Inc. ELV and Humana Inc. HUM.
Elevance Health’s AI tool speeds up the prior authorization process by aligning necessary documentation with medical policies, helping patients receive faster approvals. ELV’s system undergoes thorough evaluations to check for bias and performance. At the same time, Humana is embracing AI to reduce administrative hurdles and enhance care coordination. By automating processes like claims, risk scoring and workflow decisions, HUM is focused on boosting efficiency while ensuring that care delivery remains seamless.
UnitedHealth’s Price Performance, Valuation & Estimates
Shares of UNH have declined 35.8% in the past year compared with the industry’s fall of 29.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 18.63, above the industry average of 15.48. UNH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UnitedHealth’s 2025 earnings is pegged at $16.30 per share, implying a 41.1% drop from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Naming Top 10 Stocks for 2026
Want to be tipped off early to our 10 top picks for the entirety of 2026? History suggests their performance could be sensational.
From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.
Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2026. Don’t miss your chance to get in on these stocks when they’re released on January 5.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Elevance Health, Inc. (ELV) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

AI Takes Center Stage at UNH: Will It Fix Administrative Waste?

Below is Validea's guru fundamental report for ELEVANCE HEALTH INC (ELV). Of the 22 guru strategies we follow, ELV rates highest using our Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.
ELEVANCE HEALTH INC (ELV) is a large-cap value stock in the Insurance (Accident & Health) industry. The rating using this strategy is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of ELEVANCE HEALTH INC
More Information on Martin Zweig
About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in "Dirty Harry", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.
Additional Research Links
Dividend Aristocrats 2025
Excess Returns Investing Podcast
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Martin Zweig Detailed Fundamental Analysis - ELV

The S&P 500 Index ($SPX) (SPY) today is up by +0.63%, the Dow Jones Industrials Index ($DOWI) (DIA) is up by +0.52%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up by +1.08%. March E-mini S&P futures (ESH26) are up +0.61%, and March E-mini Nasdaq futures (NQH26) are up +1.09%.
Stock indexes are moving higher today as a rally in cloud infrastructure stocks improves market sentiment and lifts the broader market. Oracle is up by more than 7% after TikTok CEO Chew said his company has signed binding agreements to create a US joint venture owned by American investors, including Oracle. Also, strength in chipmakers today supports the broader market.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
Higher bond yields are limiting gains in stocks today, as the 10-year T-note yield is up +3 bp to 4.15%. Global bond yields are climbing today, led by a surge in the 10-year Japanese government bond yield to a 26-year high of 2.025% after the BOJ raised interest rates and said it will keep raising rates if its economic and price outlook is realized.
Upbeat comments today from New York Fed President John Williams were supportive for stocks but negative for bonds, as he said some data we're seeing is "pretty encouraging" and he sees no sign of sharp deterioration in the jobs data. He added that he sees US GDP growth of 1.5% to 1.75% this year, with growth picking up next year, and that there's "no urgency to need to act further on monetary policy right now, because I think the cuts we've made have positioned us really well."
Stock market moves may be exaggerated and more volatile than usual today due to the expiration of options, futures, and derivatives during the quarterly event known as triple witching. According to Citigroup, a record $7.1 trillion of notional open interest will roll off the US options market today.
This week's market focus will be on US economic news. Later today, Nov existing home sales are expected to be up +1.2% m/m to 4.15 million. Also, the University of Michigan Dec consumer sentiment index is expected to be revised upward by +0.2 to 53.5 from the previously reported 53.3.
The markets are discounting a 20% chance that the FOMC will cut the fed funds target range by 25 bp at the next FOMC meeting on January 27-28.
Overseas stock markets are higher today. The Euro Stoxx 50 is up +0.04%. China’s Shanghai Composite climbed to a 1-week high and closed up +0.36%. Japan’s Nikkei Stock 225 closed up +1.03%.
Interest Rates
March 10-year T-notes (ZNH6) today are down by -7 ticks. The 10-year T-note yield is up +2.7 bp to 4.149%. Today's strength in stocks has reduced safe-haven demand for government debt securities and is weighing on T-notes. Also, hawkish comments from New York Fed President John Williams are undercutting T-note prices after he said some of the data we're seeing is "pretty encouraging" and that he sees no sign of sharp deterioration in the jobs data. In addition, T-notes have a negative carryover from today’s jump in the 10-year Japan government bond yield to a 26-year high of 2.025%.
The steepening yield curve is also bearish for T-note prices. Steepening trades occur when bond investors buy short-term government debt and sell long-term debt. The yield curve has steepened since last Wednesday’s FOMC meeting, when the Fed said it would begin purchasing up to $40 billion of short-term T-bills a month to boost liquidity in the financial system. Longer-term Treasury securities are also under pressure from concerns about inflation and the Fed’s independence.
European government bond yields are moving higher today. The 10-year German bund yield is up +3.4 bp to 2.884%. The 10-year UK gilt yield is up +3.8 bp to 4.518%.
German Nov PPI fell -2.3% y/y, weaker than expectations of -2.2% y/y and the steepest pace of decline in 20 months.
The German Jan GfK consumer confidence index unexpectedly fell -3.5 to a 1.75-year low of -26.9, weaker than expectations of an increase to -23.0.
UK Nov retail sales ex-auto fuel unexpectedly fell -0.2% m/m, weaker than expectations of an increase of +0.1% m/m.
Swaps are discounting a 1% chance for a -25 bp rate cut by the ECB at its next policy meeting on February 5.
US Stock Movers
Cloud infrastructure stocks are rallying today as they recover from a recent sell-off on financing concerns in the AI supply chain. CoreWeave (CRWV) is up +8%, and Oracle (ORCL) is up more than +7% to lead gainers in the S&P 500. Also, Applied Digital (APLD) is up more than +4%, and Nebius Group NV (NBIS) is up more than +3%.
Chip stocks are moving higher today, a supportive factor for the overall market. Micron Technology (MU) is up more than +6% to lead gainers in the Nasdaq 100. Also, Lam Research (LRCX) is up more than +3%, and Nvidia (NVDA) is up more than +2% to lead gainers in the Dow Jones Industrials. In addition, Advanced Micro Devices (AMD), Applied Materials (AMAT), KLA Corp (KLAC), NXP Semiconductors NV (NXPI), and Intel (INTC) are up more than +2%. Finally, GlobalFoundries (GFS), Broadcom (AVGO), and Marvell Technology (MRVL) are up more than +1%.
Cryptocurrency-exposed stocks are climbing today, with Bitcoin (^BTCUSD) up more than +2%. Galaxy Digital Holdings (GLXY) and Riot Platforms (RIOT) are up more than +4%. Also, Strategy (MSTR) and Mara Holdings (MARA) are up more than +2%, and Coinbase Global (COIN) is up more than +1%.
Whitefiber Inc (WYFI) is up more than +16% following the announcement of a 10-year 40 megawatt co-location agreement between its subsidiary Enovum Data Centers Corp. and Nscale Global Holdings, representing around $865 million in contracted revenue.
Echostar Corp (SATS) is up more than +4% after Deutsche Bank raised its price target on the stock to $131 from $97.
Generac Holdings (GNRC) is up more than +2% after Wells Fargo Securities upgraded the stock to overweight from equal weight with a price target of $195.
Stryker Corp (SYK) is up more than +1% after Citizens JMP Securities LLC upgraded the stock to outperform from market perform with a price target of $440.
Cummins Inc (CMI) is up more than +1% after Barclays upgraded the stock to overweight from equal weight with a price target of $546.
Lamb Weston Holdings (LW) is down more than -19% to lead losers in the S&P 500 after forecasting full-year net sales of $6.35 billion to $6.55 billion, the midpoint below the consensus of $6.52 billion.
Nike (NKE) is down more than -9% to lead losers in the Dow Jones Industrials after forecasting Q3 revenue down in the low single digits and gross margins down about 175 to 225 basis points, amid persistent weakness in China.
KB Home (KBH) is down more than -7% after reporting Q4 EPS of $1.55, weaker than the consensus of $1.79, and forecasting 2026 housing revenue of $5.10 billion to $6.10 billion, the midpoint below the consensus of $5.83 billion.
Lyft Inc (LYFT) is down more than -4% after Wedbush Securities downgraded the stock to underperform from neutral with a price target of $16.
KBR Inc (KBR) is down more than -4% after Truist Securities cut its price target on the stock to $50 from $62.
Paychex (PAYX) is down more than -3% to lead losers in the Nasdaq 100 after BMO Capital Markets said the company’s Q2 earnings signaled an “okay quarter,” but management-solutions growth was softer.
FedEx (FDX) is down more than -2% after Morgan Stanley downgraded the stock to underweight from neutral with a price target of $210.
Elevance Health (ELV) is down more than -1% after Deutsche Bank downgraded the stock to hold from buy, citing a challenging macro environment.
Earnings Reports(12/19/2025)
Carnival Corp (CCL), Conagra Brands Inc (CAG), Lamb Weston Holdings Inc (LW), Paychex Inc (PAYX).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks Supported by Strength in Cloud Stocks and Chip Makers

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $119.5 million dollar outflow -- that's a 3.2% decrease week over week (from 57,250,000 to 55,400,000). Among the largest underlying components of IYH, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.3%, HCA Healthcare Inc (Symbol: HCA) is down about 0.7%, and Elevance Health Inc (Symbol: ELV) is lower by about 1.5%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average:
Looking at the chart above, IYH's low point in its 52 week range is $53.35 per share, with $66.91 as the 52 week high point — that compares with a last trade of $64.81. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Top Stocks Held By Nelson Peltz
ROL RSI
EDZ YTD Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	15.62 21.19
Price/Sales	0.57 3.02
P/B	2.27 2.24
P/FCF	112.06 18.80

Indicator	TTM Median
ROE	15.44 24.85
ROA	5.70 6.38
ROI	9.84 9.94
Net Worth	100.08 0.21
Quick Ratio	0.00 1.71
Current Ratio	1.50 2.80

Indicator	TTM Median
Net Profit Margin	3.68 11.05
Operating Margin	5.40 14.24
Gross Margin	17.36 68.98
Return on tangible equity	120.28 52.87

Indicator	TTM Median
EPS	8.37 0.37
EPS Forecast	9.70 0.37
Revenue	45.11B 17.00M
Gross Profit	7.06B —
EBITDA	2.00B —

Elevance Health, Inc.

TTM metrics for the latest quarter under IFRS and their historical dynamics

Valuation

Debts

Efficiency

Other ratios

Revenue